Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could Pre-Surgery radiation stop liver cancer from coming back?

NCT ID NCT04587739

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether giving focused radiation to a liver tumor a few weeks before surgery is safe and practical. The goal is to kill microscopic cancer cells around the tumor that often cause the cancer to return after surgery. Thirty patients with a single liver cancer nodule will receive radiation followed by standard surgery, and researchers will monitor how many are unable to complete the planned surgery due to side effects or disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this approach could reduce the chance of liver cancer returning after surgery by destroying microscopic tumor cells around the main nodule.
What could go wrong
This is a very small, early-phase safety study with only 30 participants. The radiation could cause serious side effects or delay surgery, and it may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biopsy-proven hepatocellular carcinoma or EASL/AASLD criteria * Single nodule, 3 to 8 cm of largest diameter * Hepatocellular carcinoma eligible for conventional liver resection with curative intent (R0), without preoperative portal vein embolization Exclusion Criteria: * Performance status \> 2 * Severe comorbidity with contraindication for either surgery or radiation therapy * Decompensated liver cirrhosis (Child-Pugh B or C) * Neoplastic portal vein thrombosis or extra-hepatic metastases * Previous anticancer therapy within the last 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hop Claude Huriez Chu Lille

    RECRUITING

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.